Kelun-Biotech Ignites Global Health Offensive with $250M War Chest!
- Kelun-Biotech (6990.HK) secures a staggering US$250 million in a strategic share placement, signaling a bold leap forward2.
- This monumental capital infusion is set to turbocharge research, accelerate global clinical trials, and expand its revolutionary product pipeline, with a keen focus on conquering cancer2.
- Bolstered by resounding international investor confidence, the company is on a mission to deliver life-altering therapies to patients worldwide2.
In a decisive move that reverberates through the global biopharmaceutical landscape, Kelun-Biotech has announced a landmark placement of 5,918,000 H shares, raising approximately US$250 million2. This isn't just a financial transaction; it's a declaration of intent. The net proceeds are earmarked to fuel an aggressive expansion of its research and development, expedite critical clinical trials, secure registration filings, and scale up manufacturing and commercialization of its innovative drug candidates2.
A subsidiary of Kelun Pharmaceutical (002422.SZ)1, 3, Kelun-Biotech is laser-focused on tackling some of the world's most challenging diseases, including solid tumors and autoimmune conditions2, 4. With over 30 innovative drug projects already in motion—three approved, one at NDA stage, and more than ten in clinical trials—the company is a powerhouse of medical innovation2, 4. Its pioneering OptiDC™ ADC platform stands as a testament to its technological prowess, with one ADC drug already on the market and another nearing approval3, 5.
Dr. Michael Ge, CEO, hailed the placement as a reflection of "strong recognition of Kelun-Biotech's long-term investment value." He affirmed, "With the support of this financing, we aim to further strengthen our pipeline strategy and accelerate global clinical development. This will enable us to unlock the potential of cutting-edge therapies and deliver innovative treatments to benefit more cancer patients"2. As Kelun-Biotech prepares to showcase results from six clinical studies at the 2025 ASCO Annual Meeting4, this fresh capital injection positions them to transform the future of medicine and offer new hope to millions.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.